[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clostridium-butyricum-miyairi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clostridium-butyricum-miyairi":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100625397","pan-clo-bu-pancreas-clostridium-butyricum-100625397",false,"NCT07422103","PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)","Supplementation With Clostridium Butyricum CBM588 in Patients Undergoing Pancreaticoduodenectomy for Periampullary Neoplasms: A Prospective Randomized Double-Blind Study","PAN-CLO-BU","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Patients undergoing pancreaticoduodenectomy\n* Candidates for upfront surgery without previous neoadjuvant chemotherapy or radiotherapy\n* Patients with benign or malignant periampullary neoplasms\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Previous or current use of Clostridium butyricum CBM588\n* Lactose intolerance\n* Neoadjuvant chemotherapy or radiotherapy","ALL","18 Years",{"count":20,"type":21},158,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, randomized, double-blind, single-center clinical trial designed to evaluate the effects of Clostridium butyricum CBM588 supplementation on postoperative diarrhea, gastrointestinal symptoms, and quality of life in patients undergoing pancreaticoduodenectomy for periampullary neoplasms. Oncological outcomes, including disease-free survival and overall survival, will be monitored as secondary endpoints during follow-up.",[27,28,29,30,31,32],"Pancreatic Cancer","Pancreatic Diseases","Gastrointestinal Symptoms","Clostridium Butyricum Miyairi","Pancreatoduodenectomy","CBM588",[27,28,29,30],"NOT_YET_RECRUITING","2026-02-12",{"date":37,"type":38},"2026-02-19","ACTUAL",{"date":40,"type":21},"2026-03-15",{"date":42,"type":21},"2030-11-30",{"name":44,"class":45},"Casa di Cura Dott. Pederzoli","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100558218","the-clinical-application-of-clostridium-butyricum-miyairisan-for-motor-and-non-motor-symptoms-in-parkinsons-disease-100558218","NCT06548256","The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease","Inclusion Criteria:\n\n* Male or female over 20 years old, diagnosed with Parkinson's disease.\n\nExclusion Criteria:\n\n* People with Parkinson's disease Dementia, or Lactose Intolerance","20 Years","90 Years",{"count":56,"type":21},400,[24],"This is an open-label, single-center, non-randomized study to assess the efficacy of Clostridium Butyricum Miyairi on the motor and non-motor symptoms of Parkinson's disease",[30,60],"Parkinson Disease","RECRUITING","2024-08-08",{"date":64,"type":38},"2024-08-12",{"date":66,"type":38},"2023-10-31",{"date":68,"type":21},"2026-12-31",{"name":70,"class":45},"Kaohsiung Medical University Chung-Ho Memorial Hospital"]